Survey of Pediatric Dermatologist Views on Treatment for Alopecia Areata

    December 2023 in “ JAAD international
    David Bitterman, Dov Bitterman, Jacquelyn R. Sink, Katya Harfmann, Marcia Hogeling, Christine T. Lauren, Kimberly D. Morel, Leslie Castelo‐Soccio, Nanette B. Silverberg
    Image of study
    TLDR Pediatric dermatologists have varied preferences for treating alopecia areata in children, with no standard FDA-approved treatments and some using JAK inhibitors despite risks.
    The document is a survey of pediatric dermatologists' treatment preferences for pediatric alopecia areata (PAA). The survey revealed that for PAA patients under 8 years, the primary treatment was class 1 and 2 topical corticosteroids, with secondary treatments including intralesional triamcinolone, topical immunotherapy, and minoxidil 5% solution for those with less than 25% scalp involvement. For patients 8 years and older, class 1 corticosteroids and intralesional triamcinolone were the first-line treatments, with intralesional triamcinolone and topical minoxidil 5% solution as second-line treatments. The survey also found that despite the lack of FDA-approved therapies for PAA, many pediatric dermatologists are using topical and oral Janus kinase inhibitors (JAKi) in treatment, indicating a need for further studies on the safety and efficacy of JAKi for pediatric AA. The study's limitations include selection bias, sample size, and a skew towards junior respondents.
    Discuss this study in the Community →

    Cited in this study

    1 / 1 results

    Related

    1 / 1 results